Canaccord Genuity Raises Price Target for Hillman Solutions to $15.00 USD.

Canaccord Genuity analyst Brian McNamara raised his price target for Hillman Solutions (HLMN) to $15.00 USD, a 15.38% increase, while maintaining a "Buy" rating. Hillman Solutions is a provider of hardware-related products and related merchandising services to retail markets in North America. The average target price from 8 analysts is $11.72, with an upside of 18.07% from the current price. The average brokerage recommendation is 2.1, indicating "Outperform" status. The estimated GF Value for Hillman Solutions in one year is $9.70, suggesting a downside of 2.27% from the current price.

Canaccord Genuity analyst Brian McNamara has raised his price target for Hillman Solutions Corp. (NASDAQ: HLMN) to $15.00 USD, representing a 15.38% increase, while maintaining a "Buy" rating. This update comes on the heels of the company's second-quarter earnings report, which exceeded market expectations. Hillman Solutions, a provider of hardware-related products and related merchandising services to retail markets in North America, reported better-than-expected Q2 2025 results. Hardware and Protective Solutions sales increased by 9% year-over-year, while Robotics and Digital Solutions grew by 2% year-over-year [1].

The company's stock price closed 19% higher following the earnings announcement, outperforming the Russell 2000 index, which gained 1%. The stock has delivered an impressive 21% return over the past week, though the Relative Strength Index (RSI) indicates overbought conditions. Hillman Solutions also announced its first share repurchase program, authorizing up to $100 million for repurchasing outstanding common stock [1].

The average target price from 8 analysts is $11.72, with an upside of 18.07% from the current price. The average brokerage recommendation is 2.1, indicating an "Outperform" status. The estimated GF Value for Hillman Solutions in one year is $9.70, suggesting a downside of 2.27% from the current price [2].

In addition to the earnings report, Hillman Solutions also announced a clinical trial collaboration with Actuate Therapeutics, Inc., which has initiated a Phase 1b trial of elraglusib in combination with Incyte’s PD-1 inhibitor, retifanlimab, and modified FOLFIRINOX as frontline therapy in advanced pancreatic adenocarcinoma. The trial is being conducted in collaboration with UPMC Hillman Cancer Center and Incyte Corporation [2].

References:
[1] https://www.investing.com/news/analyst-ratings/canaccord-genuity-raises-hillman-solutions-stock-price-target-to-15-on-strong-q2-93CH-4172986
[2] https://www.ainvest.com/news/hillman-solutions-corp-shares-rise-3-41-intraday-actuate-therapeutics-announced-clinical-trial-collaboration-upmc-hillman-cancer-center-2508/